c'est mort ! décison FDA tombée :

"but does see potential promise...if there's more data"

Ca veut dire qu'on est reparti pour un tour avec d'autres études complémentaires ou bien ?

ilbaritz a écrit:

"but does see potential promise...if there's more data"

Ca veut dire qu'on est reparti pour un tour avec d'autres études complémentaires ou bien ?

Il faut attendre le communiqué Cox, mais ça y ressemble!

Qui disait que Cox lui avait appris la patience?

quand je pense aux trois camions qui étaient remplis de toutes les analyses ..

c'était des Majorette leurs camions !

( désolé ,c'est nerveux

Nouveau communiqué Reuters ..on est un peu plus dans la nuance

UPDATE 2-NicOx's arthritis drug rejected by US advisers
Wed May 12, 2010 6:49pm EDT
NicOx S.A.

* FDA panel recommends against approval

* Drug has potential, but not
enough data-FDA panel * FDA
expected to make final decision by July 23
(Adds comments from panelist and FDA, background, share price,
byline) By Susan
Heavey SILVER SPRING, Md.,
May 12 (Reuters) - NicOx SA's (NCOX.PA)
arthritis drug should not be approved until there is more data
to prove it is safe, a U.S. Food and Drug Administration
advisory panel said on Wednesday.
The French biotech company wants the FDA's approval to
market its first product, a non-steroidal anti-inflammatory
drug (NSAID) called naproxcinod, to treat patients with
osteoarthritis with the claim that it has fewer heart risks
than some other drugs. In a 16-1
vote against approval, the panel said that data
from the company's small trials was not sufficient to support
safe use of the drug, which may be widely used by older people
with other health problems who are likely to be taking other
medications. One panelist abstained. The biotech had been planning to partner with a larger drug
maker to market the product. The
FDA will weigh the panel's recommendation before making
its final decision, expected by July 23. It often follows
panelists' advice. "It's really
something that's at the margins," panel member
Robert Harrington, a Duke University Medical Center
cardiologist, said of the drug. While "there's actually a lot
to be hopeful about," the company's data simply did not meet
FDA's standards, he said. The
FDA's panel of outside medical experts agreed that more
options were needed to treat the growing number of people with
arthritis, a painful joint disease. NicOx told the FDA's panel that naproxcinod was an improved
version of naproxen, a widely used NSAID that can increase
blood pressure and cause stomach problems. The company said
naproxcinod did not cause such side effects because of its
nitric oxide-releasing properties. Such a claim would set the drug apart from dozens of
over-the-counter and prescription pain relievers, including
AstraZeneca Plc (AZN.L)
(AZN.N)
and Pozen Inc's (POZN.O)
recently-approved naproxen-based drug Vimovo. Nonprescription strength naproxen is sold
over the counter
as Bayer AG's (BAYGn.DE)
Aleve. Naproxcinod would also
compete against Pfizer Inc's (PFE.N)
Celebrex, another type of pain medicine known as a COX-2 drug. Panelists echoed FDA staff concerns that
the biotech's
clinical trials did not prove its drug had a significant heart
benefit. "There is some
tantalizing data that may suggest that there
may be a protective effect ... but that will take long-term
studies to determine," said panel chairwoman Kathleen O'Neil, a
pediatric rheumatologist at the University of Oklahoma College
of Medicine. Most of the panelists
agreed that NicOx's drug appeared to
be more effective than a sugar-pill but was not necessarily
shown to be as effective as naproxen. FDA officials at the meeting called the company's data
"unclear." NicOx officials said
they would continue talking with the
FDA and would not withdraw their application. They said they
were heartened that the panel noted the need for additional
medications and that the drug was more effective than a
placebo. "We remain convinced that
this drug is viable," said
Elizabeth Robinson, a co-founder of NicOx and president of the
NicOx Research Institute. The company is also seeking approval
in Europe.
(Reporting by Susan Heavey)

les commentaires des experts me donnent vraiment cet impression :

"le médicament a l'air super, dommage qu'on ne puisse l'accepter car ce n'est pas nous qui l'avons trouvé. Un bon partenariat (ou opa) d'une pharma américaine et la porte vous sera grande ouverte.
Allez y les gars, on a préparé le terrain, maintenant vous pouvez l'achever (Nicox) et on s'en mettra plein les fouilles."

la suite, c'est que nicox est rachetée par un gros labo amaericain pour pas grand chose et refait des etudes et nouveau apssage fda avec succes. Entre temps le pp francais l'a dans le cul...
classique des ricains...

gambit33500 a écrit:

la suite, c'est que nicox est rachetée par un gros labo amaericain pour pas grand chose et refait des etudes et nouveau apssage fda avec succes. Entre temps le pp francais l'a dans le cul...
classique des ricains...

sauf si on attend pour sortir au bon moment. Il y aura bien spéculation à un moment donné. Et puis MG saura toujours rassembler autour de lui

petite question simpliste :
est ce que ca inciterait M. Garuffi à comprendre que le partenariat est nécessaire et qu'à avoir les yeux plus gros que le ventre ,il se mange le tapis (et nous avec)

ilbaritz a écrit:

petite question simpliste :
est ce que ca inciterait M. Garuffi à comprendre que le partenariat est nécessaire et qu'à avoir les yeux plus gros que le ventre ,il se mange le tapis (et nous avec)

qui va signer un partenariat pour un produit retoqué par FDA ??????????

ilbaritz a écrit:

petite question simpliste :
est ce que ca inciterait M. Garuffi à comprendre que le partenariat est nécessaire et qu'à avoir les yeux plus gros que le ventre ,il se mange le tapis (et nous avec)

je crois que le bon mot est "obligerait"

en attendant c'est vrai...qui a acheté ces millions de titres entre 5,99 et 6,23 hier , presque 7,5M de titres ..ca n'est quand même pas que du trading intra day